Anatomical main group
S – SINNESORGANE
21Decisions
23Patient groups
Added benefit by patient group
- Considerable1
- Minor1
- Non-quantifiable3
- Not proven18
Subgroups
- S01 OPHTHALMIKA 21 decisions
Decisions, newest first
- 2025-10-16LytenavaBevacizumabNot proven
- 2025-03-20AkantiorPolihexanidNon-quantifiable
- 2025-02-20VabysmoFaricimabNot proven: 2 of 2 patient groups
- 2024-05-02BeovuBrolucizumabNot proven
- 2023-06-15RoclandaLatanoprost/NetarsudilNot proven
- 2023-04-06VabysmoFaricimabNot proven
- 2023-04-06VabysmoFaricimabNot proven
- 2022-10-20BeovuBrolucizumabNot proven
- 2022-09-15LuxturnaVoretigen NeparvovecConsiderable
- 2022-09-15RaxoneIdebenonNon-quantifiable
- 2021-07-15DucressaLevofloxacin/DexamethasonNot proven
- 2019-04-04JetreaOcriplasminMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-05-03OxervateCenegerminNon-quantifiable
- 2016-05-19EyleaAfliberceptNot proven
- 2015-09-03EyleaAfliberceptNot proven
- 2015-06-18TaptiqomTafluprost/TimololNot proven
- 2015-03-05EyleaAfliberceptNot proven
- 2014-03-20EyleaAfliberceptNot proven
- 2013-12-19NevanacNepafenacNot proven
- 2013-06-06EyleaAfliberceptNot proven
- 2012-01-19YelloxBromfenacNot proven
Data status: 2026-10-29